Keros Therapeutics, Inc. (KROS) Misses Q1 EPS by 14c
Tweet
Share
E-mailGet Alerts KROS Hot Sheet
Join SI Premium – FREE
Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q1 EPS of ($1.26), $0.14 worse than the analyst estimate of ($1.12).
For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Hesai Group (HSAI) Tops Q1 EPS by 8c
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
